Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Tecentriq 1200mg Injection:
Tecentriq 1200mg Injection is a monoclonal antibody medication containing atezolizumab, primarily used in the treatment of cancer. It operates by targeting and inhibiting the immune system's ability to recognize and attack cancer cells through the blockade of PD-L1 protein present on the surface of cancer cells.
Uses of Tecentriq 1200mg Injection:
Tecentriq (atezolizumab) is employed in the treatment of various cancers, including triple-negative breast cancer, non-small cell lung cancer, and bladder cancer.
Mechanism of Action of Tecentriq 1200mg Injection:
Tecentriq 1200mg Injection is an immunotherapy medication that disrupts the interaction between PD-L1, a protein expressed by certain cancer cells, and PD-1, a receptor on immune cells. By inhibiting this interaction, atezolizumab prevents cancer cells from evading immune surveillance and enhances the immune system's ability to recognize and combat cancer cells.
Side effects of Tecentriq 1200mg Injection:
Tecentriq 1200mg Injection may induce adverse effects, similar to other medications. Common side effects include fatigue, nausea, loss of appetite, coughing, and fever. Less frequent but more severe adverse effects may include immune-related conditions such as pneumonitis (lung inflammation), colitis (colon inflammation), and hepatitis (liver inflammation). It is crucial to promptly report any side effects to a healthcare professional.